Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer

 
• By Alaric DeArment

Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.

Digital illustration of Cancer cell in colour background
Karyopharm announced topline results from its Phase III SIENDO trial in endometrial cancer • Source: Shutterstock

More from Anticancer

More from Therapy Areas